The US Food and Drug Administration (FDA) recently announced that cannabinoid (CBD) products need new regulations from Congress and cannot be marketed as dietary supplements.
CBD is the non-psychoactive compound found in marijuana and hemp plants. It grew in popularity due to its uses: as food additives, pain relief oils and nutrition supplements, which, in turn, calls for FDA regulation.
And the FDA is reluctant to give a nod citing health safety concerns associated with the long-term use of CBD.
In its statement, the administration points to studies that indicate “harm to the liver, interactions with certain medications and possible harm to the male reproductive system,” associated with the use of CBD.